专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20100285036A1 Anti-CD100 Neutralizing Antibodies and Methods of Using the Same 有权
标题翻译：抗CD100中和抗体及其使用方法
公开(公告)号：US20100285036A1
公开(公告)日：2010-11-11
申请号：US12776187
申请日：2010-05-07
申请人： Ernest S. Smith , Terrence Lee Fisher
发明人： Ernest S. Smith , Terrence Lee Fisher
IPC分类号： A61K39/395 , C07K16/18 , C07H21/00 , C12N15/63 , C12N5/07 , C12P21/00 , A61P29/00 , A61P37/02 , A61P19/02 , A61P35/00
CPC分类号： C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
摘要翻译：提供组合物和方法用于治疗与CD100相关的疾病，包括某些自身免疫疾病，炎性疾病和癌症。特别地，已经开发了抗CD100单克隆抗体来中和CD100。

12. 发明授权

US07807168B2 Selection of human TNFα specific antibodies 失效
标题翻译：人类TNFα特异性抗体的选择
公开(公告)号：US07807168B2
公开(公告)日：2010-10-05
申请号：US12100008
申请日：2008-04-09
申请人： Ernest S. Smith , Leslie A. Croy , Maria G. M. Scrivens
发明人： Ernest S. Smith , Leslie A. Croy , Maria G. M. Scrivens
IPC分类号： A61K39/395
CPC分类号： C07K16/241 , C07K2317/24 , C07K2317/565 , C07K2317/92
摘要： The invention relates to antibodies which bind to tumor necrosis factor α (TNFα) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e.g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNFα-mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNFα to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e.g. rheumatoid arthritis (RA), using antibodies of the invention.
摘要翻译：本发明涉及结合肿瘤坏死因子α（TNFα）的抗体及其用途，特别是用于诊断和治疗自身免疫性疾病的抗体。类风湿关节炎（RA）。提供抑制TNFα介导的信号通路的特异性人单克隆抗体及其变体，片段及其衍生物。还提供阻断TNFα与其受体结合的能力的特异性人单克隆抗体，以及这些抗体的片段，变体和衍生物。本发明还包括编码上述抗体或其片段，变体或衍生物的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。本发明还包括诊断和治疗自身免疫疾病的方法，例如，类风湿性关节炎（RA），使用本发明的抗体。

13. 发明授权

US07067251B2 Methods of directly selecting cells expressing inserts of interest 有权
标题翻译：直接选择表达目的片段的细胞的方法
公开(公告)号：US07067251B2
公开(公告)日：2006-06-27
申请号：US09818991
申请日：2001-03-28
申请人： Maurice Zauderer , Ernest S. Smith
发明人： Maurice Zauderer , Ernest S. Smith
IPC分类号： C12Q1/68 , C12N15/86 , C12N15/87 , C07H21/04
CPC分类号： C12N15/1079 , C12N15/1034 , C12N2799/023
摘要： The present invention relates to a high efficiency method of introducing DNA into linear DNA viruses such as poxvirus, a method of producing libraries in linear DNA viruses such as poxvirus, and methods of selecting polynucleotides of interest based on cell nonviability or other phenotypes.
摘要翻译：本发明涉及将DNA引入线性DNA病毒如痘病毒的高效方法，在线性DNA病毒如痘病毒中产生文库的方法，以及基于细胞不稳定性或其他表型选择目的多核苷酸的方法。

14. 发明授权

US08834883B2 Anti-VEGF antibodies and uses thereof 有权
标题翻译：抗VEGF抗体及其用途
公开(公告)号：US08834883B2
公开(公告)日：2014-09-16
申请号：US13703947
申请日：2011-06-14
申请人： Leslie A. Croy , Mark J. Paris , Ernest S. Smith
发明人： Leslie A. Croy , Mark J. Paris , Ernest S. Smith
IPC分类号： C07K16/22 , C07K14/475 , G01N33/53 , A61K51/10 , A61K47/48 , A61K39/395
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K2317/24 , C07K2317/76 , C07K2317/92 , G01N33/74 , G01N2333/475
摘要： Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.
摘要翻译：提供特异性结合血管内皮生长因子（VEGF）的单克隆抗体及其抗原结合片段。抗VEGF单克隆抗体阻断VEGF与其受体（例如VEGFR1和/或VEGFR2）结合并阻止VEGF的VEGFR2磷酸化。还提供了使用单克隆抗VEGF抗体治疗疾病（包括癌症）的方法。

15. 发明申请

US20130202615A1 ANTI-VEGF ANTIBODIES AND USES THEREOF 有权
标题翻译：抗VEGF抗体及其用途
公开(公告)号：US20130202615A1
公开(公告)日：2013-08-08
申请号：US13703947
申请日：2011-06-14
申请人： Leslie A. Croy , Mark J. Paris , Ernest S. Smith
发明人： Leslie A. Croy , Mark J. Paris , Ernest S. Smith
IPC分类号： C07K16/22 , A61N5/10 , A61K45/06 , G01N33/74 , A61K47/48 , A61K39/395
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K2317/24 , C07K2317/76 , C07K2317/92 , G01N33/74 , G01N2333/475
摘要： Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.
摘要翻译：提供特异性结合血管内皮生长因子（VEGF）的单克隆抗体及其抗原结合片段。抗VEGF单克隆抗体阻断VEGF与其受体（例如VEGFR1和/或VEGFR2）结合并阻止VEGF的VEGFR2磷酸化。还提供了使用单克隆抗VEGF抗体治疗疾病（包括癌症）的方法。

16. 发明授权

US07919594B2 Human anti-CD100 antibodies 有权
标题翻译：人抗CD100抗体
公开(公告)号：US07919594B2
公开(公告)日：2011-04-05
申请号：US12030356
申请日：2008-02-13
申请人： Ernest S. Smith , Terrence Lee Fisher, Jr. , Maurice Zauderer
发明人： Ernest S. Smith , Terrence Lee Fisher, Jr. , Maurice Zauderer
IPC分类号： C12P21/08 , C07K16/00 , C07K17/00 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen or a CD100 antigen located on the surface of a human CD100-expressing cell, wherein the antibody has CD100 blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD100 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD100 antibodies.
摘要翻译：提供用于治疗与CD100相关的疾病的组合物和方法，包括某些类型的癌症，自身免疫疾病，包括中枢神经系统（CNS）和周围神经系统（PNS）炎性疾病，移植排斥和侵袭性血管发生的炎性疾病。组合物包括能够结合位于人CD100表达细胞表面的可溶性人CD100抗原或CD100抗原的抗CD100抗体，其中所述抗体具有CD100阻断活性，其通过具有至少一种优化的CDR或FWR 在抗体的可变区内工程化。组合物还包括单克隆抗体的抗原结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体氨基酸序列的分离的核酸分子。本发明还包括药物组合物，其包含本发明的抗CD100抗体或其药学上可接受的载体中的抗原结合片段，变体或衍生物，以及这些抗CD100抗体的使用方法。

17. 发明授权

US07919095B2 Anti-IL-6 monoclonal antibodies 失效
标题翻译：抗IL-6单克隆抗体
公开(公告)号：US07919095B2
公开(公告)日：2011-04-05
申请号：US11882751
申请日：2007-08-03
申请人： Ernest S. Smith , Wei Wang
发明人： Ernest S. Smith , Wei Wang
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/248 , C07K2317/56 , C07K2317/565 , C07K2317/73
摘要： The present invention provides novel monoclonal antibodies that bind specifically to IL-6. The antibodies of the invention comprise a variable heavy chain (VH) region selected from any of the VH regions disclosed herein as well as amino acid variants thereof, and/or a variable light chain (VL) region selected from any of the VL regions disclosed herein as well as amino acid variants thereof. The invention also provides methods of treating diseases and disorders associated with IL-6 expression and/or activity.
摘要翻译：本发明提供了特异性结合IL-6的新单克隆抗体。本发明的抗体包含选自本文公开的任何VH区的可变重链（VH）区及其氨基酸变体，和/或选自公开的任何VL区的可变轻链（VL）区本文以及其氨基酸变体。本发明还提供了治疗与IL-6表达和/或活性相关的疾病和病症的方法。

18. 发明申请

US20080219971A1 HUMAN ANTI-CD100 ANTIBODIES 有权
标题翻译：人抗CD100抗体
公开(公告)号：US20080219971A1
公开(公告)日：2008-09-11
申请号：US12030356
申请日：2008-02-13
申请人： Ernest S. Smith , Terrence Lee Fisher , Maurice Zauderer
发明人： Ernest S. Smith , Terrence Lee Fisher , Maurice Zauderer
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N15/00 , C12N5/00 , C12P21/04
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen or a CD100 antigen located on the surface of a human CD100-expressing cell, wherein the antibody has CD100 blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD100 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD100 antibodies.
摘要翻译：提供用于治疗与CD100相关的疾病的组合物和方法，包括某些类型的癌症，自身免疫疾病，包括中枢神经系统（CNS）和周围神经系统（PNS）炎性疾病，移植排斥和侵袭性血管发生的炎性疾病。组合物包括能够结合位于人CD100表达细胞表面的可溶性人CD100抗原或CD100抗原的抗CD100抗体，其中所述抗体具有CD100阻断活性，其通过具有至少一种优化的CDR或FWR 在抗体的可变区内工程化。组合物还包括单克隆抗体的抗原结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体氨基酸序列的分离的核酸分子。本发明还包括药物组合物，其包含本发明的抗CD100抗体或其药学上可接受的载体中的抗原结合片段，变体或衍生物，以及这些抗CD100抗体的使用方法。

19. 发明申请

US20080167193A1 In Vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells 有权
标题翻译：在真核细胞中产生和鉴定免疫球蛋白分子的体外方法
公开(公告)号：US20080167193A1
公开(公告)日：2008-07-10
申请号：US11892027
申请日：2007-08-17
申请人： Maurice Zauderer , Ernest S. Smith
发明人： Maurice Zauderer , Ernest S. Smith
IPC分类号： C40B10/00
CPC分类号： C07K16/00 , C07K2317/21 , C07K2317/22 , C07K2317/55 , C07K2317/622 , C12N2799/023
摘要： The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.
摘要翻译：本发明涉及在真核细胞中表达免疫球蛋白分子的高效方法。本发明进一步涉及一种生产免疫球蛋白重链和轻链文库的方法，特别是使用三分子重组方法在真核细胞中表达。本发明还提供了选择和筛选抗原特异性免疫球蛋白分子及其抗原特异性片段的方法。本发明还提供用于产生，筛选和选择抗原特异性免疫球蛋白分子的试剂盒。最后，本发明提供了通过本文提供的方法产生的免疫球蛋白分子及其抗原特异性片段。

20. 发明授权

US3976224A Collapsible dispensing tubes 失效
标题翻译：可折叠分配管
公开(公告)号：US3976224A
公开(公告)日：1976-08-24
申请号：US520088
申请日：1974-11-01
申请人： Kenneth R. Ericson , Ernest S. Smith
发明人： Kenneth R. Ericson , Ernest S. Smith
IPC分类号： B65D35/02 , B65D35/10 , B65D35/08
CPC分类号： B65D35/10 , B65D35/02 , Y10T428/2495 , Y10T428/31692
摘要： A collapsible dispensing tube is formed from a laminate which includes two separate layers of metallic foil; e.g., aluminum. This configuration allows substantially independent variation of the deadfold (i.e., tendency of the tube to stay in the rolled-up position) and body (i.e., tendency of the tube to resist being rolled-up) of such a tube. Species of the invention having both desirable deadfold and desirable body are disclosed.
摘要翻译：可折叠的分配管由层压体形成，层压体包括两个分开的金属箔层; 例如铝。这种构造允许这种管的基本上独立的变形（即，管保持在卷起位置中的倾向）和主体（即，管被抵抗卷起的倾向）。公开了具有期望的折叠和期望的身体的本发明的物种。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式